Strategy of Continued Versus Interrupted Novel Oral Anti-coagulant at Time of Device Surgery in Patients With Moderate to High Risk of Arterial Thromboembolic Events

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE3

Total Enrollment

663 participants

Study Classification

INTERVENTIONAL

Study Start Date

2013-01-31

Study Completion Date

2018-05-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The purpose of this study is to determine the best strategy to manage novel oral anti-coagulants (NOACs) at the time of pacemaker or defibrillator surgery. The Investigators hypothesize that performing device surgery without interruption of the novel oral anti-coagulant will result in a reduced rate of clinically significant hematoma.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Perioperative Anticoagulant Use for Surgery Evaluation -2 (PAUSE-2) Study Patients Receiving a Direct Oral Anticoagulant (DOACs-Dabigatran, Rivaroxaban, Apixaban or Edoxaban) and Needing Elective High-Bleed-Risk Surgery or an Invasive Procedure

NCT06957366

Atrial Fibrillation (AF) VTE

RECRUITING NA

Perioperative Anticoagulant Use for Surgery Evaluation Study Part 2 Pilot

NCT04192552

Atrial Fibrillation

UNKNOWN NA

Anticoagulant Therapy During Pacemaker Implantation

NCT00479362

Hemorrhage Thrombosis Embolism

COMPLETED PHASE4

Prevention of Silent Cerebral Thromboembolism by Oral Anticoagulation With Dabigatran After Pulmonary Vein Isolation for Atrial Fibrillation

NCT02067182

Atrial Fibrillation Cardioembolic Events Oral Anticoagulation

COMPLETED PHASE4

Observatory of Invasive Procedures and Bleeding in Patients Treated With New Oral Anticoagulants

NCT02185027

Venous Thromboembolism Atrial Fibrillation

COMPLETED

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

This is a prospective, open-label, randomized trial, with 1:1 randomization to either continued NOAC or interrupted NOAC in patients with non-rheumatic atrial fibrillation or atrial flutter and at moderate to high risk of arterial thrombo-embolic events who require device surgery.

All patients in the study will be receiving Dabigatran or Rivaroxaban or Apixaban for at least 5 days prior to enrollment. The peri-operative management of the NOAC the patient is receiving is randomized to Interrupted NOAC or Continued NOAC.

Interrupted NOAC arm:

1. Interrupted Dabigatran

* based on renal function, patients will discontinue Dabigatran 1 day before surgery if GFR \> 50 mL/min, and 2 days before surgery if GFR is 30-50 mL/min.
* Dabigatran will be resumed at the next regular dose time, \> or = 24 hours after the end of surgery.
2. Interrupted Rivaroxaban

* patients will discontinue Rivaroxaban 1 full day before surgery.
* Rivaroxaban will be resumed at the next regular dose time, \> or = 24 hours after the end of surgery.
3. Interrupted Apixaban

* patients will discontinue Apixaban 1 full day before surgery.
* Apixaban will be resumed at the next regular dose time, \> or = 24 hours after the end of surgery.

Continued NOAC arm:

-patients will continue their chronic dose of Dabigatran or Rivaroxaban or Apixaban throughout.

All patients will have a baseline clinical lab test of serum creatinine or GRF measured.

Patients will be seen post-op on the day of their surgery for assessment of the surgical site and each day throughout their hospital stay by a blinded member of the research team. A telephone follow-up will be done on day 3-4 post surgery by an unblinded team member. All patients are seen 1-2 weeks post-op at their first routine post-op device clinic visit, for surgical site assessment by the blinded assessor and to complete Quality of Life questionnaires. Patients will be seen for assessment in the case of any bleeding or development of pocket swelling or hematoma. Patients developing a hematoma will be followed until resolution of the hematoma.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Hematoma

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

TREATMENT

Blinding Strategy

SINGLE

Outcome Assessors

Intervention Type DRUG

NOAC

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Dabigatran

NOAC

Intervention Type DRUG

Rivaroxaban

NOAC

Intervention Type DRUG

Apixaban

NOAC

Intervention Type DRUG

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

Pradaxa Xarelto Eliquis

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* any patient undergoing device surgery (ie. de novo device implant or pulse generator change or lead replacement or pocket revision)
* receiving Dabigatran or Rivaroxaban or Apixaban for at least 5 days prior to enrollment
* non-rheumatic atrial fibrillation and/or atrial flutter at moderate or high risk of ATE defined as: i) CHA2DS2VASc score greater than or equal to 2 OR ii) CHA2DS2VASc score \< 2 with plan for cardioversion or defibrillation threshold testing at time of device surgery

Exclusion Criteria

* unable or unwilling to provide informed consent
* history of noncompliance of medical therapy
* active device infection
* eGFR \< 30 mL/min
* contraindication to NOAC
* rheumatic valvular disease with hemodynamically significant valve lesion
* mechanical heart valve

Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No